-
Mashup Score: 3
Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Amivantamab Plus Chemo Nearly Doubles Time to Treatment Discontinuation, Need for Subsequent Therapy in EGFR Exon 20+ NSCLC - 1 month(s) ago
Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Amivantamab Plus Chemo Nearly Doubles Time to Treatment Discontinuation, Need for Subsequent Therapy in EGFR Exon 20+ NSCLC - 1 month(s) ago
Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Amivantamab Plus Chemo Nearly Doubles Time to Treatment Discontinuation, Need for Subsequent Therapy in EGFR Exon 20+ NSCLC - 2 month(s) ago
Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC @myESMO #ELCC24 #lcsm #oncology https://t.co/IIQ0TvmaNR